Intraocular avastin (bevacizumab) for neovascularisation of the iris and neovascular glaucoma.
- Author:
Jacob Y C CHENG
1
;
Doric W K WONG
;
Chong Lye ANG
Author Information
- Publication Type:Case Reports
- MeSH: Adult; Aged; Angiogenesis Inhibitors; administration & dosage; therapeutic use; Antibodies, Monoclonal; administration & dosage; therapeutic use; Antibodies, Monoclonal, Humanized; Bevacizumab; Glaucoma, Neovascular; drug therapy; Humans; Iris; blood supply; Male
- From:Annals of the Academy of Medicine, Singapore 2008;37(1):72-74
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTIONThe aim of this study was to determine the effectiveness of intraocular injections of bevacizumab for neovascularisation of the iris and neovascular glaucoma.
CLINICAL PICTUREThree patients with neovascularisation of the iris due to various causes were recruited.
TREATMENTPatients were treated with intraocular bevacizumab.
OUTCOMENeovascularisation of the iris was noted to have completely regressed as early as 3 days after the injection and in all the patients (100%) within 8 days after injection. They were followed up for at least 1 month with no clinical evidence of recurrence. Visual acuity remained stable or improved, and the intraocular pressure was controlled in all the 3 patients' eyes. Vitreous haemorrhage also cleared. No signs of inflammation or complications were observed.
CONCLUSIONIntraocular injection of bevacizumab is effective and safe for patients with neovascularisation of the iris and neovascular glaucoma with or without vitreous haemorrhage.
